PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

PROKIDNEY CORP.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$1.40+0.06 (+4.89%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

PROKIDNEY CORP. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	0.89	0.08	0	0	–	–
Research & Development	114	128	107	82	46	21
General & Administrative	52	56	45	71	8.86	5.98
Operating Expenses	166	184	152	153	55	27
Operating Income	-165	-184	-152	-153	-55	-27
Interest Expense	0.00	0.01	0.01	0.22	0	0
Asset Impairment Charges	0.32	5.32	0	0	–	–
Gain (Loss) on Investments	3.42	7.00	6.02	0	–	–
Gain (Loss) on Sale of Assets	-1.43	-0.06	-0.02	0	0	–
Pretax Income	-151	-164	-129	-147	-55	-27
Income Tax Expense	0.41	-0.60	6.00	0.90	0.04	-0.23
Net Income incl. Noncontrolling Interests	-152	-163	-135	-148	-55	-27
Net Income	-69	-61	-35	–	-55	–
EPS (Basic)(per share)	–	–	–	-0.23	–	–
EPS (Diluted)(per share)	–	–	–	-0.23	–	–
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	62	–	–
Shares Outstanding (Diluted, Weighted)(shares)	–	–	–	62	–	–
EBITDA	-158	-178	-148	-150	-53	-26

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -21664.5%
Net margin: -10288.4%
Return on equity, FY2025: 6.9%

Financial strength

Current ratio: 8.36
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 329.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –